Free
Articles  |   July 2003
Weight of the Evidence in Statin Clinical Trials: Comparing the Results
Author Notes
Article Information
Cardiovascular Disorders / Preventive Medicine
Articles   |   July 2003
Weight of the Evidence in Statin Clinical Trials: Comparing the Results
The Journal of the American Osteopathic Association, July 2003, Vol. 103, S4-S11. doi:
The Journal of the American Osteopathic Association, July 2003, Vol. 103, S4-S11. doi:
Abstract

This review of lipid-lowering trials looks at both the primary and secondary prevention of coronary heart disease. It also introduces evidence pointing toward the emerging importance of nonlipid risk factors in the pathogenesis of atherosclerosis. This review is designed to enhance the primary care physician's working knowledge of the evidence supporting the importance of LDL-C reduction and the central role of statin therapy in the reduction of the risk of coronary heart disease, as well as provide a greater understanding of emerging risk factors.

 Dr Clearfield has served on speakers bureaus for AstraZeneca, Merck & Co, Pfizer Inc, and Sankyo Pharma Inc, and he has received grant/research support from AstraZeneca and Pfizer Inc.